Glycosaminoglycans: Clinical use

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue 2, 1996, Pages 209-212

  Boneu, Bernard ^a  

^a CHU PURPAN   (France)

Author keywords

Dermatan sulfate; Glycosaminoglycans; Heparin; Low molecular weight heparin; Orgaran

Indexed keywords

ANTICOAGULANT AGENT; DANAPAROID; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN;

ARTERY THROMBOSIS; BLEEDING; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0030003270     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-999010     Document Type: Conference Paper

References (29)

1. Verstraete M: Heparin in the prevention and treatment of arterial thromboembolism. Adv Exp Med Biol 313:249-258, 1992.
2. Hyers T, R Hull, J Weg: Antithrombotic therapy for venous thromboembolic disease. Chest 95(Suppl):37s-51s, 1989.
3. Collins R, A Scrimegeour, S Yusuf, D Phil, R Peto: Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 31: 1162-1173, 1988.
4. Leyvras P, J Richard, F Bachmann, G Van Melle, JM Treyvaud, JJ Livio, G Candardjis: Adjusted versus fixed dose subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement. N Engl J Med 309:954-958, 1983.
5. Leizorovicz A, MC Haugh, FR Chapuis, MM Samama, JP Boissel: Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 305:913-920, 1992.
6. Nurmohamed MT, FR Rosendaal, HR Büller, E Dekker, DW Hommes, E Vandenbroucke Briel: Low molecular weight heparin versus standard heparin in general orthopaedic surgery: A meta-analysis. Lancet 340:152-156, 1992.
7. Huber O, H Bounameaux, F Borst, A Rohner: Postoperative pulmonary embolism after hospital discharge. Arch Surg 127:310-313, 1992.
8. Barritt DW, SC Jordan: Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet i:1309-1312, 1960.
9. Chiu HM, J Hirsh, WL Yung, E Regoeczi, M Gent: Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 49:171-184, 1977.
10. Hirsh J: Relationship between dose, anticoagulant effect and the clinical efficacy and safety of heparin. Adv Exp Med Biol 313: 283-295, 1992.
11. Briant L, C Caranobe, S Saivin, P Sié, B Bayrou, G Houin, B Boneu: Unfractionated heparin and CY216: Pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemostas 61:348-353, 1989.
12. Benchekroun S, B Eychenne, O Mericq, A Colombani, P Doust-Blazy, A Barret, P Sié, B Boneu: Heparin half-life and sensitivity in normal subjects and in patients affected by deep vein thrombosis. Eur J Clin Invest 16:536-539, 1986.
13. Young E, M Prins, MN Levine, J Hirsh: Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemostas 67:639-643, 1992.
14. Young E, B Cosmi, J Weitz, J Hirsh: Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemostas 70:625-630, 1993.
15. Hommes DW, A Bura, L Mazzolai, HR Büller, JW ten Cate: Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med 116:279-284, 1992.
16. Callus A, I Jackaman, J Tillett, W Mills, A Wycherley: Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet ii:1293-1296, 1986.
17. Hull RD, GE Raskob, D Rosenbloom, AA Panju, E Brill-Edwards, JS Ginsberg, J Hirsh, GJ Martin, D Green: Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 322:1260-1264, 1990.
18. Leizorovicz, A, G Simonneau, H Decousus, JP Boissel: Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis: A meta-analysis. Br Med J 309:299-309, 1994.
19. Hull RD, GE Raskob, GF Pineo, D Green, A Trowbridge, CG Elliott, RG Lerner, J Hall, T Sparling, HR Bretell: Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 326:975-982, 1992.
20. Boneu B: Low molecular weight heparin therapy: Is monitoring needed? Thromb Haemostas 72:330-342, 1994.
21. Buchanan MR, B Boneu, F Ofosu, J Hirsh: The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effect of heparin. Blood 65:198-201, 1985.
22. Van Ryn-McKenna J, FA Ofosu, E Gray, J Hirsh, MR Buchanan: Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. Ann NY Acad Sci 556:304-312, 1989.
23. Dol F, G Houin, M Rostin, JL Montastruc, D Dupouy, F Gianese, P Sié, B Boneu: Pharmacokinetics and pharmacodynamics of dermalan sulfate in man. Blood 74:1577-1582, 1989.
24. Saivin S, F Dol, C Caranobe, M Petitou, JC Lormeau, P Sié, G Houin, B Boneu: Influence of molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbit. Thromb Res 66:527-535, 1992.
25. Prandoni P, F Meduri, S Cuppini, A Toniato, F Zangrandi, P Polistena, F Gianese, A Maffei Faccioli: Dermatan sulfate: A safe approach to prevention of postoperative deep vein thrombosis. Br J Surg 79:505-509, 1992.
26. Agnelli G, B Cosmi, P Di Filippo, V Ranucci, F Veschi, M Longetti, C Renga, F Barzi, F Gianese, L Lupattelli, E Rinonapoli, GG Nenci: A randomised, double-blind, placebo-controlled trial of dermatan sulfate for prevention of deep vein thrombosis in hip fracture. Thromb Haemostas 67:203-208, 1992.
27. Lane DA, K Ryan, H Ireland, JR Curtis, M Nurmohamed, RT Krediet, M Roggekamp, P Stevens, JW ten Cate: Dermatan sulphate in haemodialysis. Lancet 339:334-335, 1992.
28. Bergqvist D, B Lindblad, T Mätzch: Glycosaminoglycans in prophylaxis against venous thromboembolism. Adv Exp Med Biol 313:259-274, 1992.
29. Magnani H: Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemostas 70:554-561, 1993.